The British scientist who led the research underpinning AstraZeneca’s coronavirus vaccine said at the weekend that a new jab could be developed against the emerging Omicron variant “very rapidly” if needed.
Professor Andrew Pollard, director of the Oxford Vaccine Group, also said existing vaccines should work against the new strain, but that would only become apparent after more research in the coming weeks.
“It’s extremely unlikely that a reboot of a pandemic in a vaccinated population like we saw last year (with the Delta variant) is going to happen,” he told BBC radio.
But if required, “The processes of how one goes about developing a new vaccine are increasingly well-oiled, so if it’s needed that is something that could be moved very rapidly.”
In a statement, AstraZeneca said it had “developed, in close collaboration with Oxford University, a vaccine platform that enables us to respond quickly to new variants that may emerge”.
The UK-based drugs company said it was “already conducting research in locations where the variant has been identified”.
Vaccine makers Pfizer/BioNTech, Moderna and Novavax have also said they are confident of being able to combat the Omicron strain.
